

# Novel imidazo[2,1-*b*]thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation

Faika Başoğlu<sup>1,2</sup>  | Nuray Ulusoy-Güzeldemirci<sup>1</sup> | Gülşen Akalın-Çiftçi<sup>3</sup> | Serap Çetinkaya<sup>4</sup> | Abdulilah Ece<sup>5</sup> 

<sup>1</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey

<sup>2</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, European University of Lefke, Northern Cyprus, Turkey

<sup>3</sup>Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey

<sup>4</sup>Department of Molecular Biology and Genetics, Science Faculty, Sivas Cumhuriyet University, Sivas, Turkey

<sup>5</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Biruni University, Istanbul, Turkey

## Correspondence

Faika Başoğlu, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, 34116, Istanbul, Turkey.  
Email: fabasoglu@eul.edu.tr

Abdulilah Ece, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Biruni University, 34010, Istanbul, Turkey.  
Email: aece@biruni.edu.tr

## Funding information

Istanbul Üniversitesi

## Abstract

The purpose of this study was to synthesize imidazo[2,1-*b*]thiazole derivatives, characterize them with spectroscopical techniques and investigate for cytotoxic and apoptotic effects on glioma C6 cancer cell line. The in vitro anticancer activities were also investigated against focal adhesion kinase. Most of the compounds, particularly the derivatives carrying 3-oxo-1-tiya-4-azaspiro[4.5]decane moiety, exhibited higher or comparable activities in comparison with the reference drug, cisplatin. Compounds with methyl, propyl, phenyl moieties at the eighth and second position of the spirothiazolidinone ring showed high FAK inhibitory activities. In addition, molecular docking studies shed light on the binding modes of the synthesized compounds. The critical interactions with amino acid residues located in the active site were revealed. The results obtained from both biological assay data and computational results might provide insight into developing new inhibitors against focal adhesion kinase.

## KEYWORDS

focal adhesion kinase, Imidazo[2,1-*b*]thiazole, molecular docking

## 1 | INTRODUCTION

Cancer (carcinoma) is one of the serious diseases that are still being studied extensively. Among the most aggressive human cancers are gliomas, a type of primary malignant brain tumour. Despite advances in regular therapy, patients with gliomas have a low prognosis. At the present day, adjuvant chemotherapy and radiotherapy are administered to glioma patients after surgery. The efficacy of chemotherapy is limited because

of problems in drug delivery and inherent radio, and chemoresistance (Lin et al., 2017; Patil et al., 2013). Therefore, the development of novel anticancer drugs that possess good biological activity and fewer side-effects are required.

In medicinal chemistry, imidazo[2,1-*b*]thiazoles have a broad spectrum of pharmacological activities including antiviral (Conti et al., 2019), antibacterial (Atta et al., 2011; Gadad et al., 2000; Mohan & Kiran, 1991), antifungal (Çapan et al., 1999; Juspın et al., 2010; Ulusoy et al., 2002) and

antitumor (Andreani et al., 1982; Andreani et al., 1992, 1993) activities. Moreover, the clinical efficacies of tiazofurin, dasatinib and bleomycins have indicated the importance of incorporating the thiazole moiety in antitumor drug design (Paunescu et al., 2015; Rouf & Tanyeli, 2015).

Focal adhesion kinase (FAK) is a tyrosine kinase that plays a major role in cellular survival and movement pathways. FAK is a potential target for the prevention and treatment of both primary cancers and tumour metastasis (Frisch et al., 1996; Ilic et al., 1995; Mitra et al., 2005). Only in the past decade, phase I and II clinical trials have been initiated for small molecule inhibitors of FAK (Infante et al., 2012; Shanthi et al., 2014; Yoon et al., 2015). Therefore, inhibition of FAK activity may be a novel strategy for cancer therapy.

Previous studies reported that compounds carrying imidazole and thiazole rings display anticancer activity by inhibiting FAK (Dao et al., 2015; Jain et al., 2013; Lv et al., 2018).

The present study aims to investigate the synthesis of a series of novel imidazo[2,1-*b*]thiazole derivatives, which include either N-cyclohexylidene or 3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl that could have potential anticancer activity. The characterization of these compounds with spectroscopic techniques was also carried out, and *in vitro* anticancer activities were evaluated. Additionally, computational studies were employed to gain new insights into interaction modes of the compounds with the active site of FAK.

## 2 | METHODS AND MATERIALS

### 2.1 | Experimental

Details for general synthesis procedure for the compounds are given in supplementary data. All synthesized compounds were recrystallized from 96% ethanol. After the purification, white solid powders were obtained with good yield.

Elemental analyses were carried out on a Thermo Finnigan Flash EA 1,112 elemental analyser. Melting points were examined using a Büchi B-540 melting point apparatus in open capillary tubes and are uncorrected. FT-IR spectra were recorded on KBr discs, using a Shimadzu IR Affinity-1 FT-IR spectrophotometer. <sup>1</sup>H-NMR, <sup>13</sup>C-NMR (APT), <sup>13</sup>C-NMR (DEPT) and HSQC (<sup>1</sup>H-<sup>13</sup>C) spectra were measured on a Varian UNITY INOVA (500 MHz) spectrometer using DMSO-*D*<sub>6</sub>. Mass spectra were recorded on a Thermo Finnigan LCQ Advantage Max instrument.

### 2.2 | Biochemistry

#### 2.2.1 | Cell culture method

In Dulbecco's Modified Eagle's Medium (DMEM - Sigma, Deisenhofen, Germany) supplemented with 10% foetal

bovine serum (Gibco, Paisley, UK), NIH/3T3 mouse embryonic fibroblast cells and Glioma C6 rat cancer cells were brooded. All of the media were put in with 100 IU/ml penicillin-streptomycin (Gibco, Paisley, UK), and the cells were incubated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air. Exponentially growing cells were plated at 2 × 10<sup>4</sup> cells/mL into 96-well microtiter tissue culture plates (Nunc, Roskilde, Denmark) and were incubated for 24 hr before the supplementation of the compounds. The stock solutions of compounds were prepared with DMSO (dimethyl sulfoxide), and extra dilutions were done using the fresh culture medium. Finally, DMSO's concentration in the last culture medium was less than 0.1% (Ciftci et al., 2015).

#### 2.2.2 | MTT assay for cytotoxicity of compounds

The level of cellular reduction of tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by mitochondrial succinate dehydrogenase was quantified as previously described in the literature with small modifications (Scheuber et al., 1983). After 24 hr of preincubation, the tested compounds and cisplatin (positive control) were added to give final concentration in the range 3.9–500 µg/ml, and the cells were incubated for 24 hr. Then, MTT was added to a final concentration of 0.5 mg/ml, and the cells were incubated for further four hours at 37°C. After the medium was removed, the formazan crystals were solubilized by the addition of 200 µl DMSO to each well and absorbance was read at 540 nm with a microtitre plate spectrophotometer (Bio-Tek plate reader, Winooski, VT, USA). Every concentration was repeated in three wells, and IC<sub>50</sub> values were defined as the drug concentrations that reduced absorbance to 50% of the control values (Ciftci et al., 2015).

In the present study, the degree of selectivity index (SI) of the synthetic compounds is expressed as follows:

$SI = IC_{50}$  of pure compound in a normal cell line /  $IC_{50}$  of the same pure compound in cancer cell line, where  $IC_{50}$  is the concentration required to kill 50% of the cell population.

#### 2.2.3 | Flow cytometric analyses of apoptosis

After cells were incubated with compounds **4g**, **4k**, **5c**, **5d**, **5e**, **6a-6f** and cisplatin at  $IC_{50}$  concentrations, phosphatidylserine externalization which indicates early apoptosis was measured by Annexin V-PI (BD, Pharmingen) on a flow cytometer (BD FACS Aria) (Ciftci et al., 2015) for 24 hr. Annexin V staining protocol was applied according to the manufacturer's instructions (BD, Pharmingen). The cells were processed for

data acquisition and analysed on a Becton-Dickinson FACS Aria, which uses FACSDiva version 6.1.1. Software (Ciftci et al., 2015).

### 2.2.4 | FAK (Phospho-Tyr397) activity detection by ELISA

Initially, C6 cancer glioma cells were administrated by IC<sub>50</sub> concentrations of compounds **4c**, **4h**, **4l**, **5d**, **6b**, **6d**, **6e**, **6f** and cisplatin for 24 hr. FAK (Phospho-Tyr397) effectiveness of compounds was examined by Colorimetric Cell-Based ELISA FAK (Phospho-Tyr397) activity kit (Aviva Systems Biology, San Diego, USA) according to manufacturer's instructions (Altintop et al., 2018).

## 2.3 | Computational section

### 2.3.1 | Ligand and protein preparation

Prior to computational studies, all compounds must be prepared for calculations. Accordingly, all compounds were prepared using the LigPrep (Ligand preparation) module of the Schrödinger suite (Schrödinger, 2016a). OPLS2005 (optimized potential liquid simulations) force field was used for minimizations (Jorgensen et al., 1996; Jorgensen & Tirado-Rives, 1988; Shivakumar et al., 2010). All probable states of the compounds at pH 7.0 ± 2.0 were generated.

The molecular docking studies were performed using high resolution (2.3 Å) X-ray crystal structure of focal adhesion kinase domain (PDB ID: 2ETM) in complex with 7H-Pyrrolo[2,3-*d*]pyrimidine derivative (7PY, native ligand). The raw crystal structure was also prepared using PrepWizard (Protein Preparation Wizard) (Sastry et al., 2013) in Maestro of Schrödinger-2016 software package (Schrödinger, 2016b). As a first step, the PrepWizard was used for adding missing hydrogen atoms and removing all water molecules and heteroatoms. The native ligand was kept for binding site detection. Then, the protein structure was refined by assigning the bond orders and revising the missing side-chains. In the final step, the steric clashes between the atoms were removed by minimizing whole structure using OPLS2005 force field.

### 2.3.2 | Molecular docking

The docking calculations were carried out using Glide SP (standard precision) module (Friesner et al., 2004; Halgren et al., 2004). A grid that illustrated the binding pocket was generated. The native ligand, 7PY, was used as reference to identify the size and centre of the receptor grid.


### 2.3.3 | Calculation of the molecular properties

Some selected physicochemical properties of the synthesized compounds were calculated using the Qik-Prop module of Maestro (Table 4) (Schrödinger, 2016c).


## 3 | RESULTS AND DISCUSSION

### 3.1 | Chemistry

The rationale for the design and synthesis of *N*<sup>2</sup>-(substituted cyclohexylidene)-6-(phenyl/4-chlorophenyl)imidazo[2,1-*b*]thiazol-3-acetohydrazides and 2-[6-(phenyl/4-chlorophenyl)imidazo[2,1-*b*]thiazol-3-yl]-*N*-(2-nonsubstituted/methyl-6,7,8,9-alkyl/aryl-3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl)acetamides derivatives are based on previous studies that showed efficient anticancer potency. Both imidazo[2,1-*b*]thiazoles and thiazolidinone scaffolds are known to possess many various anticancer activities (Ali et al., 2014; Deep et al., 2015; Deng et al., 2019; Jain et al., 2012; Manasa et al., 2020; Romagnoli et al., 2015; Szychowski et al., 2017; Szychowski et al., 2017; Tahmasvand et al., 2020). Additionally, Levamisole containing imidazo[2,1-*b*]thiazole nucleus was approved by FDA in 1990 and has been used in cancer treatment since then (FDA, 2021; Moertel et al., 1995; Vacchelli et al., 2012) Those imidazo[2,1-*b*]thiazole



**SCHEME 1** Rationally designed template for the targeted compounds as potential anticancer agents



Comp.	R	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>
<b>4a</b>	H	H	Me	-	H	H
<b>4b</b>	H	Pr	H	-	H	H
<b>4c</b>	Cl	H	Me	-	H	H
<b>4d</b>	Cl	H	2-CNEt	-	H	H
<b>4e</b>	Cl	H	COOEt	-	H	H
<b>4f</b>	Cl	H	H	-	diMe	Me
<b>4g</b>	Cl	H	H	-	diMe	diMe
<b>4h</b>	Cl	Pr	H	-	H	H
<b>4i</b>	Cl	H	<i>ter</i> -butyl	-	H	H
<b>4j</b>	Cl	<i>ter</i> -butyl	H	-	H	H
<b>4k</b>	Cl	H	Ph	-	H	H
<b>4l</b>	Cl	Cl	Ph	-	H	H
<b>4m</b>	Cl	4-OHPh	H	-	H	H
<b>5a</b>	Cl	H	Me	H	H	H
<b>5b</b>	Cl	H	H	H	diMe	Me
<b>5c</b>	Cl	Pr	H	H	H	H
<b>5d</b>	Cl	<i>ter</i> -butyl	H	H	H	H
<b>5e</b>	Cl	Ph	H	H	H	H
<b>5f</b>	Cl	4-OHPh	H	H	H	H
<b>6a</b>	H	Pr	H	Me	H	H
<b>6b</b>	Cl	H	Me	Me	H	H
<b>6c</b>	Cl	H	H	Me	diMe	H
<b>6d</b>	Cl	Pr	H	Me	H	H
<b>6e</b>	Cl	<i>ter</i> -butyl	H	Me	H	H
<b>6f</b>	Cl	Ph	H	Me	H	H

**TABLE 1** IC<sub>50</sub> values of the synthesized compounds on C6 cancer cells and NIH/3T3 cell lines

Comp.	IC <sub>50</sub> (μM)			Comp.	IC <sub>50</sub> (μM)		
	C6 cell line	NIH/3T3 cell line	SI value		C6 cell line	NIH/3T3 cell line	SI values
<b>4a</b>	>500	>500	–	<b>5a</b>	68.33 ± 12.58	>500	>7.32
<b>4b</b>	>500	>500	–	<b>5b</b>	>500	>500	–
<b>4c</b>	>500	>500	–	<b>5c</b>	13.66 ± 2.08	140.0 ± 28.28	10.24
<b>4d</b>	275 ± 35.35	>500	>1.82	<b>5d</b>	12.66 ± 0.57	25.67 ± 6.03	2.03
<b>4e</b>	>500	>500	–	<b>5e</b>	19.83 ± 0.76	32.5 ± 3.54	1.64
<b>4f</b>	>500	>500	–	<b>5f</b>	>500	>500	–
<b>4g</b>	8.33 ± 2.08	>500	>60.02	<b>6a</b>	12.66 ± 0.57	156.67 ± 40.41	12.38
<b>4h</b>	>500	>500	–	<b>6b</b>	28.33 ± 2.88	57.5 ± 3.54	2.03
<b>4i</b>	>500	>500	–	<b>6c</b>	18.00 ± 2.00	39.0 ± 1.41	2.17
<b>4j</b>	106.66 ± 2.88	>500	>4.69	<b>6d</b>	10.83 ± 1.25	223.33 ± 25.17	20.62
<b>4k</b>	4.83 ± 0.28	>500	>103.5	<b>6e</b>	19.66 ± 3.21	25.0 ± 7.07	1.27
<b>4l</b>	>500	>500	–	<b>6f</b>	16.33 ± 1.52	62.5 ± 3.24	3.83
<b>4m</b>	>500	>500	–	<b>Cisplatin</b>	36 ± 8.48	ND	

Abbreviations: ND, not determined; SI, selectivity index.

**TABLE 2** Percentages of typical quadrant analysis of Annexin V FITC/Propidium iodide flow cytometry of C6 cancer cells treated with Cisplatin and most active compounds

Comp. <sup>a</sup>	Early apoptotic cells%	Late apoptotic cells%	Viable cells%	Necrotic cells%
<b>Control</b>	4.8	3.7	87.4	4.1
<b>Cisplatin</b>	2.2	10.6	75.1	12.1
<b>4g</b>	8.4	7.8	63.6	20.3
<b>4k</b>	12.9	23.4	29.0	34.7
<b>5c</b>	2.5	24.5	11.6	61.9
<b>5d</b>	7.1	6.3	77.9	13.5
<b>5e</b>	0.2	1.6	33.4	64.8
<b>6a</b>	4.7	14.9	22.0	58.5
<b>6b</b>	3.5	3.9	85.5	7.2
<b>6c</b>	4.0	7.7	79.3	9.0
<b>6d</b>	5.7	30.6	14.2	49.5
<b>6e</b>	5.6	4.0	84.3	6.1
<b>6f</b>	2.1	7.3	77.0	13.5

<sup>a</sup>C6 cancer cells were cultured for 24 hr in medium with active compounds (**4g**, **4k**, **5c**, **5d**, **5e**, **6a-f** and **cisplatin**) at IC<sub>50</sub> values. At least 10,000 cells were examined for each sample, and quadrant analysis was achieved.

derivatives were synthesized by extremely easy method with a high yield (Guzeldemirci & Kucukbasmaci, 2010).


In the current study, the target novel compounds were designed as the head group (region A), the linker chain (region B) and the tail group (region C) to shed light on future research (Scheme 1). The head group was considered as an

**TABLE 3** FAK inhibitory effects of the compounds **4c**, **4h**, **4l**, **5d**, **6b**, **6d**, **6e**, **6f** and Cisplatin on C6 cell line

Compounds	Inhibition % FAK
<b>4c (&gt;500 μM)</b>	20.58 ± 3.31
<b>4h (&gt;500 μM)</b>	21.74 ± 2.87
<b>4l (&gt;500 μM)</b>	5.93 ± 0.04
<b>5d (12.66 ± 0.57 μM)</b>	37.29 ± 2.85
<b>6b (28.33 ± 2.88 μM)</b>	68.71 ± 0.73
<b>6d (10.83 ± 1.25 μM)</b>	47.78 ± 3.93
<b>6e (19.66 ± 3.21 μM)</b>	46.64 ± 8.59
<b>6f (16.33 ± 1.52 μM)</b>	72.55 ± 3.63
<b>Cisplatin (36 ± 8.48 μM)</b>	32.03 ± 0.21

imidazo[2,1-*b*]thiazole derivative. The tail group was planned as either *N*-cyclohexylidene or 3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl, and the linker between the head and tail groups was designed as hydrazone and hydrazide, respectively. The tail group that was expected to be key important for the anticancer activity consists of 2-methylcyclohexyliden, 4-propylcyclohexyliden, 2-(2-cyanoethyl)cyclohexyliden, 2-ethoxycarbonylcyclohexyliden, 3,3,5-trimethylcyclohexyliden, 2-*tert*-butylcyclohexyliden, 2-phenylcyclohexyliden, 4-phenylcyclohexyliden, 4-(4-hydroxyphenyl) cyclohexyliden and their spirothiazolidinone derivatives.

Over and above that, substituents with different electro-negativity and size were also considered. Therefore, some small and bulky substitutions that have low electronegativity



**FIGURE 1** Flow cytometric analysis of C6 cancer cells treated with IC<sub>50</sub> values of compounds **4g**, **4k**, **5c**, **5d**, **5e**, **6a-6f** and cisplatin for 24 hr. At least 10,000 cells were examined for each sample, and quadrant analysis was carried out

**TABLE 4** Binding energies and selected molecular properties of the native ligand and compounds **4a-4m**, **5a-5f**, **6a-6f**

Compound	MW <sup>a</sup>	%HOA <sup>b</sup>	PSA <sup>c</sup>	QPlogP <sub>0</sub> /w <sup>d</sup>	DS <sup>e</sup>	MM/GBSA <sup>f</sup>
<b>4a</b>	366.4	100	69.06	5.39	-5.441	-52.572
<b>4b</b>	394.5	100	71.11	6.13	-5.606	-62.942
<b>4c</b>	400.9	100	68.13	5.52	-4.490	-50.817
<b>4d</b>	439.9	94.2	93.93	5.16	-4.651	-40.530
<b>4e</b>	548.9	100	94.07	5.52	-4.844	-61.477
<b>4f</b>	428.9	100	69.60	6.46	-5.382	-59.494
<b>4g</b>	443.0	100	68.83	6.78	-5.035	-67.270
<b>4h</b>	428.9	100	71.17	6.56	-4.801	-61.831
<b>4i</b>	443.0	100	64.45	6.84	-4.894	-65.487
<b>4j</b>	443.0	100	71.01	6.66	-5.151	-53.405
<b>4k</b>	462.9	100	68.20	7.17	-4.781	-42.677
<b>4l</b>	462.9	100	71.04	7.10	-4.637	-61.928
<b>4m</b>	478.9	100	94.75	6.46	-5.692	-64.445
<b>5a</b>	475.0	100	73.19	5.57	-6.060	-78.772
<b>5b</b>	503.0	100	73.27	6.06	-4.587	-45.650
<b>5c</b>	503.0	100	76.98	6.36	-6.617	-76.899
<b>5d</b>	517.1	100	76.99	6.53	-5.977	-82.917
<b>5e</b>	537.0	100	76.97	6.95	-5.459	-57.943
<b>5f</b>	553.0	89.07	99.51	6.26	-5.588	-60.849
<b>6a</b>	482.6	100	73.62	6.24	-4.443	-55.226
<b>6b</b>	489.0	100	68.23	5.88	-6.622	-81.730
<b>6c</b>	517.1	95.76	69.62	5.98	-5.432	-50.252
<b>6d</b>	517.1	100	74.95	6.75	-6.715	-78.799
<b>6e</b>	531.1	100	74.86	6.92	-5.762	-69.911
<b>6f</b>	551.1	100	74.94	7.64	-5.558	-70.194
<b>NL</b>	377.4	100	65.14	3.90	-7.740	-71.812

<sup>a</sup>Molecular weight (g/mol) (recommended value <500).

<sup>b</sup>Percentage oral absorption (<25% weak and >85% strong).

<sup>c</sup>Polar surface area (Å) (recommended value ≤140 Å).

<sup>d</sup>Logarithm of the octanol/water ratio coefficient of compound (recommended value <5).

<sup>e</sup>Docking Score (kcal/mol).

<sup>f</sup>MM/GBSA dG Bind Energy (kcal/mol).


such as methyl, propyl, *tert*-butyl and phenyl were chosen. Additionally, to investigate the electronegativity effect on activity, more electronegative substituents such as 2-cyanoethyl, ethoxycarbonyl and 4-hydroxyphenyl were chosen.

The synthesis of the heretofore unlisted compounds (**4a-m**, **5a-f**, **6a-f**) is outlined in Scheme 1. *N*<sup>2</sup>-(substituted cyclohexylidene)-6-(4-chlorophenyl/phenyl)imidazo[2,1-*b*]thiazol-3-acetohydrazides (**4a-4m**) was synthesized starting from 2-[6-(4-chlorophenyl/phenyl)imidazo[2,1-*b*]thiazol-3-yl]acetohydrazides and then 2-[6-(phenyl / 4-chlorophenyl)imidazo[2,1-*b*]thiazol-3-yl]-*N*-(2-nonssbstited/methyl-6,7,8,9-alkyl/aryl-3-oxo-1-thia-4-azaspiro[4.5]decan-4-yl)acetamides (**5a-5f**, **6a-6f**) were synthesized by the reaction of compounds **4a-m** with thioglycolic acid or thiolactic acid. All novel imidazo[2,1-*b*]thiazole derivatives are reported in

Scheme 2. The structures of the compounds were characterized by several spectroscopic methods.

MTT assay was used to figure out antiproliferative effectiveness of the synthesized compounds on rat glioma C6 cancer cell lines (Table 1). To investigate whether the compounds possess either non-toxic or toxic to healthy (normal) cells, the cytotoxic effects of imidazo[2,1-*b*]thiazole derivatives (**4a-4m**, **5a-5f**, **6a-6f**) on NIH/3T3 mouse embryonic fibroblast cell line were evaluated as well by MTT assay.

Because compound **6d** had critical inhibitory effects on C6 cell line with  $10.83 \pm 1.25$  µg/ml, it was identified to be the most encouraging anticancer agent among the series of the synthesized compounds. This result showed that the propyl substituent on the cyclohexane ring at the 4th position of the azaspiro[4.5]decane moiety considerably increased



**FIGURE 2** 2D ligand interaction diagram for NL (Top), active compound **6d** (middle) and inactive compound **4h** (bottom). H-bond is represented purple arrow

anticancer activity against the C6 cancer cell line by inducing apoptosis. Also, this compound had selectivity by its low toxic effect on towards the NIH/3T3 cell line.


The ketone-hydrazone derivatives (except compound **4d**, **4j**, **4g** and **4k**) among the synthesized compounds did not exhibit cytotoxic activity against C6 cancer cell line ( $IC_{50} > 500 \mu M$ ). Compounds **4d** and **4j** expressed cytotoxic activity with  $IC_{50}$  values of  $275 \pm 35.35$  and  $106.66 \pm 2.88 \mu M$ , respectively. However, compounds **4g** and **4k** exhibited considerable cytotoxic effect with  $IC_{50}$  values of  $8.33 \pm 2.08$  and  $4.83 \pm 0.28 \mu M$ , respectively. Also, the cytotoxicity of the compounds was low against NIH/3T3 cell line (Table 1).

As the SI demonstrates the differential activity of compounds, the greater the SI value is, the more selective it is. According to the calculated SI data shown in Table 1, the selectivity index rankings are as follow; **4k**>**4g**>**6d**>**6a**>**5c**>**5a**>**4j**>**6f**>**6c**>**6b**=**5d**. The rest of the compounds displayed very low selectivity.

The apoptotic effects of the most effective anticancer agents among the new series were evaluated for C6 cancer cell lines based on Annexin V-PI binding capacities in flow cytometry. The early apoptotic effects of compound **6d** and cisplatin on the C6 cancer cell line were identified as 5.7 and 2.2%, respectively, while their late apoptotic effects were observed as 30.6 and 10.6%, respectively (Table 2 and Figure 1). The results showed that compound **6d** possessed more apoptotic activity against the C6 cancer cell line than cisplatin. Moreover, the significance of the imidazo[2,1-*b*]thiazole scaffold for apoptotic activity against the C6 cell line was clearly observed.

We should note that FAK also known as PTK2, which has been identified as a crucial regulator of growth factor receptor, is either prompted or overexpressed in various cancers (Altintop et al., 2018). Hence, FAK has been known to be a pharmacological target for preventing carcinoma, and numerous compounds that have FAK inhibitory activity have been designed and synthesized (Cao et al., 2016; Lee et al., 2015; Roy-Luzarraga & Hodivala-Dilke, 2016; Yoon et al., 2015; Zhao & Guan, 2011). Also, the significance of imidazole and thiazole derivatives as FAK inhibitors (Dao et al., 2015; Jain et al., 2013) prompted us to evaluate the inhibitory effects of compounds **4c**, **4h**, **4l**, **5d**, **6b**, **6d**, **6e**, **6f** on FAK (Phospho-Tyr397) activity (Table 3). According to the assay, we administered  $IC_{50}$  values of these compounds to C6 cell lines. Then, the OD450 values obtained for the phosphorylated FAK were normalized using the OD450 values that were obtained for GAPDH after 24 hr. Mean per

**FIGURE 3** Electrostatic potential at the binding site mapped onto the molecular surface of FAK in complexed with docked **6d** (left) and **4h** (right)



cent absorbance of untreated control cells were assumed to be 0%. Then, % inhibition rates of compounds and cisplatin administered C6 cells were calculated. Data points represent means for three independent wells. According to the assay, the most effective FAK inhibitor on C6 cancer line was determined to be compound **6f** ( $72.54925 \pm 3.63\%$ ) followed by compounds **6b** ( $68.71 \pm 0.73\%$ ), **6d** ( $47.78 \pm 3.93\%$ ) and **6e** ( $46.64 \pm 8.59\%$ ) ( $IC_{50}$  concentrations were  $16.33 \pm 1.52$ ,  $28.33 \pm 2.88$ ,  $10.83 \pm 1.25$  and  $19.66 \pm 3.21 \mu\text{M}$ , respectively). However, compounds **4c**, **4h**, **4i** and **5d** ( $20.58 \pm 3.31\%$ ,  $21.74 \pm 2.87\%$ ,  $5.93 \pm 0.04\%$  and  $37.29 \pm 2.85\%$ , respectively) did not show considerable FAK inhibition in C6 cancer cells. These results pointed out the importance of the phenyl, propyl, tert-butyl, methyl moieties at the eighth and second position of the spirothiazolidinone ring for FAK inhibitory activity.

When all results are evaluated, spirothiazolidinone derivatives seem to have higher anticancer activity than hydrazone derivatives, and interestingly, the hydrazone derivatives carrying tetramethyl and phenyl substitutions show great anticancer activity. Propyl substitution at 8th position on spirothiazolidinone ring increases activity. Additionally, small alkyl groups such as methyl boost the activity. 4-Chlorophenyl and phenyl derivatives show slightly different anticancer activity. Electronegativity might affect anticancer activity, especially for hydrazone derivatives.

In our recent studies, we have used a number of computational approaches against some important therapeutic targets (Chan et al., 2020; Ece, 2020; Ece & Pejin, 2015; Mustafa Er et al., 2018; Maryam et al., 2020; Maryam et al., 2020; Yamali et al., 2021). Hence, molecular docking simulations were implemented to see probable binding modes of the synthesized compounds. A high resolution ( $2.3 \text{ \AA}$ ) X-ray crystal structure of focal adhesion kinase domain (PDB ID: 2ETM) in complex with 7H-Pyrrolo[2,3-*d*]pyrimidine derivative (7PY, native ligand) was used in calculations. As an internal validation, co-crystallized native ligand was docked in the binding site and then both conformations were

overlayed. The RMSD value between the docked pose and the crystal conformation of the native ligand was found as  $0.651 \text{ \AA}$ . Although the docking programmes perform well in generating pharmacological active conformations of the ligands and detecting the binding modes to the receptor, the current scoring functions are not predicted to distinguish between inactive and active compounds with a high success rate (Ece & Fatma, 2013; Mascarenhas & Ghoshal, 2008; Tahtaci et al., 2018). However, we have obtained good results with Glide software previously (Er et al., 2017; Hou et al., 2011; Tahtaci et al., 2018). The docking scores of the synthesized compounds (**4a-4m**, **5a-5f**, **6a-6f**) are given together with 7PY in Table 4.

Glide docking performed well in classifying active compounds, for example **6d**, which had a higher docking score among other compounds (**4a-m**, **5a-f**, **6a-f**). The native ligand, 7PY, had the highest docking score, and it fitted the target by making hydrogen bonds with Cysteine 502 of FAK (Figure 2). As a comparison, 2D binding interaction diagrams were also depicted for one active and one inactive compound, **6d** and **4h**, respectively. As can be seen from the Figure 2, **6d** makes the same hydrogen bond with the amino acid residue, CYS 502.

In order to get more insight into the difference between the binding modes of the active and inactive compounds, the electrostatic potential map surface of the receptor and the binding surface of the ligands were drawn (Figure 3). Blue colour indicates low electron density regions, while red colour illustrates high electron density zones. The binding conformation of active compound **6d** and inactive compound **4h** look thoroughly different. The active compound **6d** has favourable electrostatic interactions with the receptor. For instance, high electron density oxygen atom of carbonyl group interacts with low electron density region of the target (Figure 3).

The binding free energies of macromolecules were calculated by MM/GBSA (Molecular Mechanics/Generalized Born Surface Area) methods using combining continuum solvation models and molecular mechanics calculations to

perform more rigorous binding affinity calculations (Hou et al., 2011). Hou et al. (2011) assessed the performance of MM/GBSA on the binding free energies. The authors reported MM/GBSA to serve as a powerful tool in ranking of inhibitors (Hou et al., 2011).

The combination of computational study and experimental findings on SAR works disclosed that the presence of spiro[4.5]decane scaffold with  $-\text{CH}_3$  at 2nd position and lipophilic groups at 8th position on spiro[4.5]decane ring has significant effects on the anticancer activity.

The calculated molecular descriptors related to drug likeness and absorption, distribution, metabolism and excretion (ADME) were all in acceptable ranges (Table 4).

## 4 | CONCLUSION

The fact that focal adhesion kinase signalling pathways can accelerate tumour progression and metastasis formation that makes it a promising therapeutic target prompted us to study novel small molecule inhibitors of this target. In the present study, novel imidazo[2,1-*b*]thiazole derivatives were obtained using simple and practical methods. Their structure was characterized using various spectroscopic methods such as FT-IR,  $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$ , HSQC, elemental analysis and mass spectroscopy. The in vitro anticancer activities were also investigated against focal adhesion kinase. Most of the compounds, especially the derivatives which carry 3-oxo-1-tiya-4-azaspiro[4.5]decane moiety, showed considerable anticancer activity. Furthermore, compounds **6b**, **6d**, **6f** carrying methyl, propyl, phenyl moieties at the eighth and second position of the spirothiazolidinone ring, showed high FAK inhibitory activities. Additionally, according to the results, compound **4k** can also be considered as a promising anticancer lead compound due to its high SI value and apoptotic effect. However, it does not show anticancer activity by inhibiting FAK. Molecular docking studies were implemented for all synthesized compounds to evaluate the probable binding modes.

The biological assay data, along with the computational results that shed light on the binding motifs and critical interactions, might provide insight into designing new inhibitors against focal adhesion kinase.

## ACKNOWLEDGEMENT

The present research was financially supported by the Research Fund of Istanbul University. Project No. 24304 and TDK-2016-20280.

## ORCID

Faika Başoğlu  <https://orcid.org/0000-0002-4890-3124>  
Abdulilah Ece  <https://orcid.org/0000-0002-3087-5145>

## REFERENCES

- Ali, A. R., El-Bendary, E. R., Ghaly, M. A., & Shehata, I. A. (2014). Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-*b*]thiazole derivatives bearing pyrazole moieties. *European Journal of Medicinal Chemistry*, 75, 492–500. <https://doi.org/10.1016/j.ejmech.2013.12.010>
- Altıntop, M. D., Sever, B., Akalin Ciftci, G., Turan-Zitouni, G., Kaplancikli, Z. A., & Ozdemir, A. (2018). Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. *European Journal of Medicinal Chemistry*, 155, 905–924. <https://doi.org/10.1016/j.ejmech.2018.06.049>
- Andreani, A., Bonazzi, D., & Rambaldi, M. (1982). Potential antitumor agents. VII. 5-Substituted 6-phenylimidazo[2,1-*b*]thiazoles. *Archiv Der Pharmazie*, 315(5), 451–456. <https://doi.org/10.1002/ardp.19823150511>
- Andreani, A., Rambaldi, M., Locatelli, A., Bossa, R., Fraccari, A., & Galatulas, I. (1993). Potential antitumor agents. XX (1) 6-anilinoimidazo[2,1-*b*]thiazoles. *Pharmaceutica Acta Helvetica*, 68(1), 21–24. [https://doi.org/10.1016/0031-6865\(93\)90004-P](https://doi.org/10.1016/0031-6865(93)90004-P)
- Andreani, A., Rambaldi, M., Locatelli, A., Bossa, R., Fraccari, A., & Galatulas, I. (1992). Potential antitumor agents. 21. Structure determination and antitumor activity of imidazo[2,1-*b*]thiazole guanylhydrazones. *Journal of Medicinal Chemistry*, 35(24), 4634–4637. <https://doi.org/10.1021/jm00102a018>
- Atta, K. F., Farahat, O. O., Ahmed, A. Z., & Marei, M. G. (2011). Synthesis and antibacterial activities of novel imidazo[2,1-*b*]-1,3,4-thiadiazoles. *Molecules*, 16(7), 5496–5506. <https://doi.org/10.3390/molecules16075496>
- Cao, F. Y., Zhou, X. P., Su, J., Yang, X. H., Mu, F. H., Shen, J. Y., & Sun, W. (2016). Chemical structure characteristics and bioactivity of small molecule FAK inhibitors. *Anti-Cancer Agents in Medicinal Chemistry*, 16(8), 934–941. <https://doi.org/10.2174/1871520616666151116122355>
- Çapan, G., Ulusoy, N., Ergenç, N., & Kiraz, M. (1999). New 6-phenylimidazo [2, 1-*b*] thiazole derivatives: Synthesis and antifungal activity. *Monatshefte Für Chemie/Chemical Monthly*, 130(11), 1399–1407. <https://doi.org/10.1007/PL00010200>
- Chan, K., Frankish, N., Zhang, T., Ece, A., Cannon, A., O'Sullivan, J., & Sheridan, H. (2020). Bioactive indanes: Insight into the bioactivity of indane dimers related to the lead anti-inflammatory molecule PH46A. *Journal of Pharmacy and Pharmacology*, 72(7), 927–937. <https://doi.org/10.1111/jphp.13269>
- Ciftci, G. A., Iscan, A., & Kutlu, M. (2015). Escin reduces cell proliferation and induces apoptosis on glioma and lung adenocarcinoma cell lines. *Cytotechnology*, 67(5), 893–904. <https://doi.org/10.1007/s10616-015-9877-6>
- Conti, I., Morigi, R., Locatelli, A., Rambaldi, M., Bua, G., Gallinella, G., & Leoni, A. (2019). Synthesis of 3-(Imidazo[2,1-*b*]thiazol-6-yl)-2H-chromen-2-one derivatives and study of their antiviral activity against parvovirus B19. *Molecules*, 24(6), <https://doi.org/10.3390/molecules24061037>
- Dao, P., Smith, N., Scott-Algara, D., Garbay, C., Herbeuval, J. P., & Chen, H. (2015). Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11. *Cancer Letters*, 360(1), 48–59. <https://doi.org/10.1016/j.canlet.2015.02.016>
- Deep, A., Kumar, P., Narasimhan, B., Ramasamy, K., Mani, V., Mishra, R. K., & Majeed, A. B. (2015). Synthesis, antimicrobial, anticancer

- evaluation of 2-(aryl)-4- thiazolidinone derivatives and their QSAR studies. *Current Topics in Medicinal Chemistry*, 15(11), 990–1002. <https://doi.org/10.2174/1568026615666150317221849>
- Deng, X., Tan, X., An, T., Ma, Q., Jin, Z., Wang, C. E., Meng, Q., & Hu, C. (2019). Synthesis, characterization, and biological activity of a novel series of Benzo[4,5]imidazo[2,1-b]thiazole derivatives as potential epidermal growth factor receptor inhibitors. *Molecules*, 24(4), 682. <https://doi.org/10.3390/molecules24040682>
- Ece, A. (2020). Towards more effective acetylcholinesterase inhibitors: A comprehensive modelling study based on human acetylcholinesterase protein–drug complex. *Journal of Biomolecular Structure and Dynamics*, 38(2), 565–572. <https://doi.org/10.1080/07391102.2019.1583606>
- Ece, A., & Pejin, B. (2015). A computational insight into acetylcholinesterase inhibitory activity of a new lichen depsidone. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 30(4), 528–532. <https://doi.org/10.3109/14756366.2014.949256>
- Ece, A., & Sevin, F. (2013). The discovery of potential cyclin A/CDK2 inhibitors: A combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies. *Medicinal Chemistry Research*, 22(12), 5832–5843. <https://doi.org/10.1007/s00044-013-0571-y>
- Er, M., Abounakhla, A. M., Tahtaci, H., Bawah, A. H., Çınaroğlu, S. S., Onaran, A., & Ece, A. (2018). An integrated approach towards the development of novel antifungal agents containing thiadiazole: Synthesis and a combined similarity search, homology modeling, molecular dynamics and molecular docking study. *Chemistry Central Journal*, 12(1), 1–21. <https://doi.org/10.1186/s13065-018-0485-3>
- Er, M., Ergüven, B., Tahtaci, H., Onaran, A., Karakurt, T., & Ece, A. (2017). Synthesis, characterization, preliminary SAR and molecular docking study of some novel substituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as antifungal agents. *Medicinal Chemistry Research*, 26, 615–630. <https://doi.org/10.1007/s00044-017-1782-4>
- FDA (2021). *Levamisole*. Retrieved from <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process>
- Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *Journal of Medicinal Chemistry*, 47(7), 1739–1749. <https://doi.org/10.1021/jm0306430>
- Frisch, S. M., Vuori, K., Ruoslahti, E., & Chan-Hui, P. Y. (1996). Control of adhesion-dependent cell survival by focal adhesion kinase. *Journal of Cell Biology*, 134(3), 793–799. <https://doi.org/10.1083/jcb.134.3.793>
- Gadad, A. K., Mahajanshetti, C. S., Nimbalkar, S., & Raichurkar, A. (2000). Synthesis and antibacterial activity of some 5-guanylhydrazono/thiocyanato-6-arylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide derivatives. *European Journal of Medicinal Chemistry*, 35(9), 853–857. [https://doi.org/10.1016/s0223-5234\(00\)00166-5](https://doi.org/10.1016/s0223-5234(00)00166-5)
- Guzeldemirci, N. U., & Kucukbasmaci, O. (2010). Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety. *European Journal of Medicinal Chemistry*, 45(1), 63–68. <https://doi.org/10.1016/j.ejmech.2009.09.024>
- Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *Journal of Medicinal Chemistry*, 47(7), 1750–1759. <https://doi.org/10.1021/jm030644s>
- Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. *Journal of Chemical Information and Modeling*, 51(1), 69–82. <https://doi.org/10.1021/ci100275a>
- Infante, J. R., Camidge, D. R., Mileskin, L. R., Chen, E. X., Hicks, R. J., Rischin, D., Fingert, H., Pierce, K. J., Xu, H., Roberts, W. G., Shreeve, S. M., Burris, H. A., & Siu, L. L. (2012). Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. *Journal of Clinical Oncology*, 30(13), 1527–1533. <https://doi.org/10.1200/JCO.2011.38.9346>
- Jain, A. K., Sharma, S., Vaidya, A., Ravichandran, V., & Agrawal, R. K. (2013). 1,3,4-thiadiazole and its derivatives: A review on recent progress in biological activities. *Chemical Biology & Drug Design*, 81(5), 557–576. <https://doi.org/10.1111/cbdd.12125>
- Jain, A. K., Vaidya, A., Ravichandran, V., Kashaw, S. K., & Agrawal, R. K. (2012). Recent developments and biological activities of thiazolidinone derivatives: A review. *Bioorganic & Medicinal Chemistry*, 20(11), 3378–3395. <https://doi.org/10.1016/j.bmc.2012.03.069>
- Jorgensen, W. L., Maxwell, D. S., & Tirado-Rives, J. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. *Journal of the American Chemical Society*, 118(45), 11225–11236. <https://doi.org/10.1021/ja9621760>
- Jorgensen, W. L., & Tirado-Rives, J. (1988). The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. *Journal of the American Chemical Society*, 110(6), 1657–1666. <https://doi.org/10.1021/ja00214a001>
- Juspín, T., Laget, M., Terme, T., Azas, N., & Vanelle, P. (2010). TDAE-assisted synthesis of new imidazo[2,1-b]thiazole derivatives as anti-infectious agents. *European Journal of Medicinal Chemistry*, 45(2), 840–845. <https://doi.org/10.1016/j.ejmech.2009.10.048>
- Lee, B. Y., Timpson, P., Horvath, L. G., & Daly, R. J. (2015). FAK signaling in human cancer as a target for therapeutics. *Pharmacology & Therapeutics*, 146, 132–149. <https://doi.org/10.1016/j.pharmthera.2014.10.001>
- Lin, L., Cai, J., & Jiang, C. (2017). Recent advances in targeted therapy for glioma. *Current Medicinal Chemistry*, 24(13), 1365–1381. <https://doi.org/10.2174/0929867323666161223150242>
- lić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., & Aizawa, S. (1995). Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. *Nature*, 377(6549), 539–544. <https://doi.org/10.1038/377539a0>
- Lv, P. C., Jiang, A. Q., Zhang, W. M., & Zhu, H. L. (2018). FAK inhibitors in cancer, a patent review. *Expert Opinion on Therapeutic Patents*, 28(2), 139–145. <https://doi.org/10.1080/13543776.2018.1414183>
- Manasa, K. L., Pujitha, S., Sethi, A., Mohammed, A., Alvala, M., Angeli, A., & Supuran, C. T. (2020). Synthesis and biological evaluation of Imidazo[2,1-b]Thiazole based sulfonyl piperazines as novel carbonic anhydrase II inhibitors. *Metabolites*, 10(4), 136. <https://doi.org/10.3390/metabo10040136>
- Maryam, A., Khalid, R. R., Siddiqi, A. R., & Ece, A. (2020). E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against

- cardiovascular diseases. *Journal of Biomolecular Structure and Dynamics*, 39(7), 2302–2317. <https://doi.org/10.1080/07391102.2020.1748718>
- Maryam, A., Khalid, R. R., Vedithi, S. C., Abdulilah, E., Çinaroğlu, S. S., Siddiqi, A. R., & Blundell, T. L. (2020). Exploring the structural basis of conformational heterogeneity and autoinhibition of human cGMP-specific protein kinase I $\alpha$  through computational modelling and molecular dynamics simulations. *Computational and Structural Biotechnology Journal*, 18, 1625–1638. <https://doi.org/10.1016/j.csbj.2020.06.016>
- Mascarenhas, N. M., & Ghoshal, N. (2008). An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation—a case study with CDK2/cyclinA. *European Journal of Medicinal Chemistry*, 43(12), 2807–2818. <https://doi.org/10.1016/j.ejmech.2007.10.016>
- Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005). Focal adhesion kinase: In command and control of cell motility. *Nature Reviews Molecular Cell Biology*, 6(1), 56–68. <https://doi.org/10.1038/nrm1549>
- Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., & Glick, J. H., ... (1995). Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. *Journal of Clinical Oncology*, 13(12), 2936–2943. <https://doi.org/10.1200/JCO.1995.13.12.2936>
- Mohan, J., Kiran, K. (1991). Novel bridgehead nitrogen heterocycles: Synthesis and antimicrobial activity of 2H-Imidazo (2, 1-b) pyrazolo (3, 4-d) thiazoles. *ChemInform*, 22(47), 898–900.
- Patil, S. A., Hosni-Ahmed, A., Jones, T. S., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013). Novel approaches to glioma drug design and drug screening. *Expert Opinion on Drug Discovery*, 8(9), 1135–1151. <https://doi.org/10.1517/17460441.2013.807248>
- Paunescu, E., Clavel, C. M., Nowak-Sliwinska, P., Griffioen, A. W., & Dyson, P. J. (2015). Improved angiostatic activity of dasatinib by modulation with hydrophobic chains. *ACS Medicinal Chemistry Letters*, 6(3), 313–317. <https://doi.org/10.1021/ml500496u>
- Romagnoli, R., Baraldi, P. G., Prencipe, F., Balzarini, J., Liekens, S., & Estevez, F. (2015). Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds. *European Journal of Medicinal Chemistry*, 101, 205–217. <https://doi.org/10.1016/j.ejmech.2015.06.042>
- Rouf, A., & Tanyeli, C. (2015). Bioactive thiazole and benzothiazole derivatives. *European Journal of Medicinal Chemistry*, 97, 911–927. <https://doi.org/10.1016/j.ejmech.2014.10.058>
- Roy-Luzarraga, M., & Hodivala-Dilke, K. (2016). Molecular pathways: Endothelial Cell FAK-A target for cancer treatment. *Clinical Cancer Research*, 22(15), 3718–3724. <https://doi.org/10.1158/1078-0432.CCR-14-2021>
- Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. *Journal of computer-aided Molecular Design*, 27(3), 221–234. <https://doi.org/10.1007/s10822-013-9644-8>
- Scheuber, P. H., Mossmann, H., Beck, G., & Hammer, D. K. (1983). Direct skin test in highly sensitized guinea pigs for rapid and sensitive determination of staphylococcal enterotoxin B. *Applied and Environment Microbiology*, 46(6), 1351–1356. <https://doi.org/10.1128/AEM.46.6.1351-1356.1983>
- Schrödinger (2016). *LigPrep*. : Schrödinger, LLC. Retrieved from <https://www.schrodinger.com/>
- Schrödinger (2016). *Maestro*. : Schrödinger, LLC. Retrieved from <https://www.schrodinger.com/>
- Schrödinger (2016). *QikProp*. : Schrödinger, LLC. Retrieved from <https://www.schrodinger.com/>
- Shanthi, E., Krishna, M. H., Arunesh, G. M., Venkateswara Reddy, K., Sooriya Kumar, J., & Viswanadhan, V. N. (2014). Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review. *Expert Opinion on Therapeutic Patents*, 24(10), 1077–1100. <https://doi.org/10.1517/13543776.2014.948845>
- Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2010). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. *Journal of Chemical Theory and Computation*, 6(5), 1509–1519. <https://doi.org/10.1021/ct900587b>
- Szychowski, K. A., Leja, M. L., Kaminsky, D. V., Binduga, U. E., Pinyazhko, O. R., Lesyk, R. B., & Gminski, J. (2017). Study of novel anticancer 4-thiazolidinone derivatives. *Chimico-Biological Interactions*, 262, 46–56. <https://doi.org/10.1016/j.cbi.2016.12.008>
- Szychowski, K. A., Leja, M. L., Kaminsky, D. V., Kryshchshyn, A. P., Binduga, U. E., Pinyazhko, O. R., & Gminski, J. (2017). Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARgamma). *European Journal of Medicinal Chemistry*, 141, 162–168. <https://doi.org/10.1016/j.ejmech.2017.09.071>
- Tahmasvand, R., Bayat, P., Vahdaniparast, S. M., Dehghani, S., Kooshafar, Z., Khaleghi, S., Almasirad, A., & Salimi, M. (2020). Design and synthesis of novel 4-thiazolidinone derivatives with promising anti-breast cancer activity: Synthesis, characterization, in vitro and in vivo results. *Bioorganic Chemistry*, 104, 104276.
- Tahtaci, H., Karacik, H., Ece, A., Er, M., & Seker, M. G. (2018). Design, synthesis, SAR and molecular modeling studies of novel Imidazo[2,1-b][1,3,4]Thiadiazole derivatives as highly potent antimicrobial agents. *Molecular Informatics*, 37(3), 1700083–1700097. <https://doi.org/10.1002/minf.201700083>
- Ulusoy, N., Kiraz, M., & Küçükbasmacı, O. (2002). New 6-(4-bromophenyl)-imidazo [2, 1-b] thiazole derivatives: Synthesis and antimicrobial activity. *Monatshfte Für Chemie/Chemical Monthly*, 133(10), 1305–1315. <https://doi.org/10.1007/s007060200108>
- Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. *Oncoimmunology*, 1(6), 894–907. <https://doi.org/10.4161/onci.20931>
- Yamali, C., Sakagami, H., Uesawa, Y., Kurosaki, K., Satoh, K., Masuda, Y., Yokose, S., Ece, A., Bua, S., Angeli, A., Supuran, C. T., & Gul, H. I. (2021). Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides. *European Journal of Medicinal Chemistry*, 217, 113351. <https://doi.org/10.1016/j.ejmech.2021.113351>
- Yoon, H., Dehart, J. P., Murphy, J. M., & Lim, S. T. (2015). Understanding the roles of FAK in cancer: Inhibitors, genetic models, and new insights. *Journal of Histochemistry and Cytochemistry*, 63(2), 114–128. <https://doi.org/10.1369/0022155414561498>

Zhao, X., & Guan, J. L. (2011). Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. *Advanced Drug Delivery Reviews*, 63(8), 610–615. <https://doi.org/10.1016/j.addr.2010.11.001>

### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Başoğlu, F., Ulusoy-Güzeldemirci, N., Akalın-Çiftçi, G., Çetinkaya, S., & Ece, A. (2021). Novel imidazo[2,1-*b*]thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation. *Chemical Biology & Drug Design*, 00, 1–13. <https://doi.org/10.1111/cbdd.13896>